Recombinant cytomegalovirus glycoprotein B vaccine: Rethinking the immunological basis of protection
Open Access
- 6 June 2018
- journal article
- editorial
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 115 (24) , 6110-6112
Abstract
Development and licensure of a vaccine against human CMV infection is a major public health priority. Although the major driving force for a CMV vaccine is prevention of congenital infection—since CMV is the most common viral cause of permanent neurodevelopmental disability in infants globally (1)—other patient populations, in particular recipients of hematopoietic stem cells and solid organ transplant (SOT) patients, could benefit from a vaccine. A number of CMV vaccines have been evaluated in clinical trials in recent years (2). These have included live, attenuated vaccines; vectored vaccines expressing CMV-encoded immunogens; and purified recombinant protein vaccines coadministered with adjuvant. The most extensively studied vaccine to date is a subunit vaccine based on the viral envelope glycoprotein B (gB; gpUL55). Two important papers published in PNAS (3, 4) provide surprising and novel insights into the protecting mechanisms conferred by this gB vaccine. How did the CMV gB emerge as a leading vaccine candidate? CMV gB is a type 1 envelope glycoprotein and class III viral fusogen (5). It is synthesized as a 906- or 907-aa polypeptide (depending upon the strain of CMV) that undergoes extensive posttranslational modification, including glycosylation at N - and O -linked sites, followed by cleavage by the ubiquitous cellular endoprotease, furin, into amino (gp90)- and carboxy (gp58)-terminal moieties (refs. 6 and 7 and Fig. 1). The gp90 and gp58 subunits are covalently connected by disulfide bonds and the mature, glycosylated gB assumes a trimeric configuration; the trimer subsequently dimerizes as the protein assumes its final envelope conformation (8). CMV gB interacts with the virally encoded glycoprotein H/L (gH/gL) complex as an essential component of the core fusion machinery required for infection and cell-to-cell spread of virus (9). Up to 70% of the virus-neutralizing capacity of CMV immune sera recognizes gB (10). Although recent studies of anti-CMV … [↵][1]1Email: schleiss{at}umn.edu. [1]: #xref-corresp-1-1Keywords
This publication has 30 references indexed in Scilit:
- Complement enhances in vitro neutralizing potency of antibodies to human cytomegalovirus glycoprotein B (gB) and immune sera induced by gB/MF59 vaccinationnpj Vaccines, 2017
- Cytomegalovirus Vaccines: Current Status and Future ProspectsDrugs, 2016
- Safety and efficacy of a cytomegalovirus glycoprotein B (gB) vaccine in adolescent girls: A randomized clinical trialVaccine, 2016
- Structure of HCMV glycoprotein B in the postfusion conformation bound to a neutralizing human antibodyNature Communications, 2015
- Strain Variation and Disease Severity in Congenital Cytomegalovirus InfectionInfectious Disease Clinics of North America, 2015
- A new look at a poorly immunogenic neutralization epitope on cytomegalovirus glycoprotein B. Is there cause for antigen redesign?Molecular Immunology, 2014
- HCMV gB shares structural and functional properties with gB proteins from other herpesvirusesVirology, 2013
- Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trialThe Lancet, 2011
- Class III viral membrane fusion proteinsCurrent Opinion in Structural Biology, 2009
- Human cytomegalovirus strain towne glycoprotein B is processed by proteolytic cleavageVirology, 1988